Our findings elucidate a mechanism whereby NETs blockade governs host defense and enhances the effectiveness of Fn14 mAb against septic AKI, thus supporting further clinical investigation of this combination strategy as a rational, therapeutic strategy to favor patients with septic AKI. The gene discussed is TNFRSF12A; the disease is acute kidney injury.